Review on the Potential Therapeutic Roles of *Nigella sativa* in the Treatment of Patients with Cancer: Involvement of Apoptosis

- Black cumin and cancer -

Hamid Mollazadeh¹, Amir R. Afshari², Hossein Hosseinzadeh³*

¹Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
²Department of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
³Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Key Words

anti-proliferative, antioxidant, apoptosis, *Nigella sativa*, cancer, programmed cell death

Abstract

*Nigella sativa* (*N. sativa*, family Ranunculaceae) is a medicinal plant that has been widely used for centuries throughout the world as a natural remedy. A wide range of chemical compounds found in *N. sativa* expresses its vast therapeutic effects. Thymoquinone (TQ) is the main component (up to 50%) in the essential oil of *N. sativa*. Also, pinene (up to 15%), p-cymene (40%), thymohydroquinone (THQ), thymol (THY), and dithymoquinone (DTQ) are other pharmacologically active compounds of its oil. Other terpenoid compounds, such as carvacrol, carvone, 4-terpineol, limonenes, and citronellol, are also found in small quantities in its oil. The main pharmacological characteristics of this plant are immune system stimulatory, anti-inflammatory, hypotensive, hepatoprotective, antioxidant, anti-cancer, hypoglycemic, anti-tussive, milk production, uricosuric, choleric, anti-fertility, and spasmytotropic properties. In this regard, we have searched the scientific databases PubMed, Web of Science, and Google Scholar with keywords of *N. sativa*, anti-cancer, apoptotic effect, antitu-

1. Introduction

Cancer is one of the most debilitating and traumatic diseases of modern life, for which no curative approach is presently available. Cancer is also the second leading cause of death [1, 2]. Due to the narrow therapeutic window of chemical drugs [3], particularly can-
paracrine treatment agents, and the development of resistance against these drugs, a need exists to discover novel natural therapies for the treatment of chronic diseases [4-7], especially cancer [8]. Even though the recent therapies used to treat patients with various types of cancer have not been completely effective, adjuvant therapies, including the use of medicinal plants, may have some effect in achieving cancer treatment goals [9]. Cell survival and proliferation are due to many factors such as apoptosis, and each factor that disturbs the balance between the cell cycle and apoptosis can lead to cell malignancy [10].

* *

**Nigella sativa* (N. sativa) has been used for medicinal purposes for centuries in traditional medicine, and its anti-cancer and anti-proliferative effects have been demonstrated in Unani, Ayurveda, and Chinese medicine [11]. The aim of this review is to highlight the role of apoptosis in the progression of cancer and to evaluate the efficacy of *N. sativa* against malignancy development in both *in vitro* and *in vivo* models. In this regard, we have searched the scientific databases PubMed, Web of Science, and Google Scholar with keywords of *N. sativa*, anti-cancer, apoptotic effect, antitumor, antioxidant, and malignancy over the period from 2000 to 2017, and we have summarized the current scientific information available on the anticancer activities of *N. sativa* and its mechanisms of action.

## 2. Apoptosis

Nowadays, a great deal of interest has been focused on comprehending the inner workings of a particular style of cell death that occurs in different cells of the human body. Apoptosis is the process of programmed cell death (PCD), it usually affects scattered individual cells rather than all the cells in a particular area, and once it is initiated, it occurs quickly. Therefore, apoptosis is a gene-regulated phenomenon that causes cell changes such as alteration of the cell's morphology, blebbing, nuclear fragmentation, cell shrinkage, chromatin condensation, chromosomal DNA fragmentation, and global mRNA decay [12, 13]. It plays a prominent role in many neurodegenerative and autoimmune diseases and disorders, as well as cancer and AIDS [14-16]. Apoptosis is also induced by different injurious stimuli such as hypoxia, radiation, reactive oxygen species, heat, and cytotoxic anticancer drugs [17].

### 2.1. Morphological and Biochemical Features of Apoptosis

The definition of apoptosis was first given by Elmore and Kerr et al. [15, 18]. The beginning of apoptosis is characterized by shrinkage of the cell and the nucleus, as well as condensation of nuclear chromatin, membrane blebbing, and oligonucleosomal DNA fragmentation [14, 19]. During the early process of apoptosis, cell shrinkage and pyknosis (which is the most distinctive feature of apoptosis and results because of chromatin condensation) occur; thus, the cells are smaller, cytoplasm is dense, and organelles are tightly packed [19, 20]. Apoptotic bodies, sometimes called ‘apobodies,’ are small sealed membrane vesicles that are produced from cells undergoing cell death by apoptosis. The formation of apoptotic bodies is a mechanism that preventing the leakage of potentially toxic or immunogenic cellular contents of dying cells, inflammation or autoimmune reactions, and tissue destruction [21, 22]. These bodies are subsequently phagocytized by macrophages, neoplastic cells, and parenchymal cells and are degraded within phagolysosomes. Because the apoptotic cells do not release their cellular components into the surrounding interstitial tissue, no inflammatory reactions related with apoptosis occur [20, 23].

The biochemical modifications of apoptotic cells are very extensive and include protein cleavage, phagocytic recognition, protein cross-linking, and DNA fragmentation [24]. Caspases (cysteine-aspartic proteases or cysteine-dependent aspartate-directed proteases) are a family of cysteine proteases that play important roles as catalysts for the central hydrolytic reactions of apoptosis, necrosis, and inflammation [25-27]. At least 12 of these enzymes are known. Caspases are extensively expressed in an inactive

---

### Table 1 Classification of caspases

| Caspases | Type (s) | Role (s) |
|----------|----------|----------|
| Initiators | 2, 8, 9, 10 | Cleave inactive pro-forms of effector caspases, thereby activating them |
| Effectors (executioners) | 3, 6, 7 | Cleave and inactivate proteins that protect living cells from apoptosis, such as the DNA repairing protein, PARP, ICAD/DFF45, and Bcl-2 proteins |
| Inflammatory | 1, 4, 5 | Have a role in the immune system |
| Others | 11 | Regulates apoptosis and cytokine maturation during septic shock |
| | 12 | Mediates endoplasmic-specific apoptosis and cytotoxicity by amyloid-β |
| | 13 | Is a bovine gene and is activated by caspase 8 |
| | 14 | Is highly expressed in embryonic tissues, but not in adult tissues |

PARP, poly ADP-ribose polymerase; Bcl2, B-cell lymphoma 2.
proenzyme form in most cells and can often activate other procaspases, allowing initiation of a protease cascade [28, 29]. Table 1 shows the classification of caspases. Mitochondrial (intrinsic) and death receptor (extrinsic) pathways are two major apoptotic pathways that have been identified [30]. These pathways are in contact and share a general final phase of apoptosis that dismantles substrates critical for cell maintenance [31]. Fig. 1 shows the apoptotic pathways and important mediators in the apoptosis process.

**Figure 1** Apoptotic pathways.
2.2. Death Receptor (Extrinsic) Apoptotic Pathway

Death receptors (transmembrane receptors - mediated interactions) are members of the tumor necrosis factor (TNF) receptor gene super family and play the main role in extrinsic signaling pathways of apoptosis. Death signals from the cell's surface are dispatched to the intracellular space with these receptors, which have cysteine-rich extracellular domains and 80-amino-acid cytoplasmic domains. In this pathway, trimeric ligands, such as TNF-J, FasL, Apo3L, Apo2L, and Apo2L, bind to clustered receptors, after which cytoplasmic adapter proteins are recruited to exhibit corresponding death domains that bind with the receptors. The adaptor proteins Fas-associated death domain (FADD) and tumor necrosis factor receptor type 1-associated death domain protein (TRADD) are the consequences of the bindings of the FasL to the Fas receptor and of the TNF ligand to the TNF receptor, respectively [32, 33]. A combination of FADD and procaspase-8 in this pathway results in the formation of the death-inducing signaling complex (DISC) and tends to activate caspase-8, after which the execution phase of apoptosis is triggered [34]. Table 2 presents additional information about the major extrinsic pathway proteins, along with their full names and roles. Another important ligand for activating the extrinsic pathway is TNF-related apoptosis-inducing ligands (TRAIL), including TNF-α and FasL, the activations of which lead to apoptotic cell death interference with TRAIL-R1 (DR4) and TRAIL-R2 (DR5) in a wide range of cultured malignant cells [35].

### Table 2

| Abbreviation(s) | Full name(s) | Role(s) |
|-----------------|--------------|---------|
| Apo2L, Apo3L    | Apo2 ligand, Apo3 ligand | Acts as ligands for initiating apoptosis |
| DED             | Death effector domain | Found in inactive procaspases and formed DISC |
| DR3, DR4, DR5   | Death receptor 3, 4, 5 | Interacts with ligands and initiates extrinsic pathway |
| Caspase 8       | Cysteiny l aspartic acid-protease 8 | Triggers execution phase of apoptosis |
| FasR            | FAS receptor | Is an example of receptors in the extrinsic pathway |
| FasL            | FAS ligand | Is an example of ligands in the extrinsic pathway |
| FADD            | Fas-associated death domain | Is an adapter protein that is recruited to the DISK during signaling via death receptors |
| RIP             | Receptor-interacting protein | Is a key effector in TNF signaling and is essential for ROS-induced cell death |
| TNF-α           | Tumor necrosis factor alpha | Regulates immune cells functions and induces apoptotic cell death |
| TNFR1           | Tumor necrosis factor receptor 1 | Mediates actions of TNF-α |
| TRADD           | TNF receptor-associated death domain | Acts as adaptor protein and mediates apoptosis signaling and NF-κB activation |

2.3. Mitochondrial Apoptotic (Intrinsic) Pathway

The intrinsic pathway is independent of receptor involvement whereas intracellular signals that act directly on targets are mitochondrial-dependent events [36]. The intrinsic pathway initiates with positive or negative stimuli, and any stimulus that fails to cause suppression of death programs, including the absence of certain growth factors, cytokines and hormones, is categorized as a negative signal. Radiation, hypoxia, toxins, hyperthermia, and so forth that can trigger apoptosis are a subset of positive stimuli [14]. Changes in mitochondrial permeability transition (MPT) lead to the loss of mitochondrial transmembrane potential. Pro-apoptotic proteins, such as cytochrome C, Smac/DIABLO, and the serine protease (as the first group) and HtrA2/Omi AIF, endonuclease G, and caspase-activated DNase (CAD) (as the second group), are extricated from the intermembrane space of the mitochondria to the cytosol [37]. The first group activates the caspase-dependent mitochondrial pathway. In this collection, cytochrome C binds and activates Apaf-1, as well as procaspase-9, forming an “apoptosome” and Smac/DIABLO, and HtrA2/Omi promotes apoptosis by inhibiting IAP (inhibitors of apoptosis protein) activity [38]. Caspase-9 activation is the main consequence of releasing pro-apoptotic proteins [39]. The second group of pro-apoptotic proteins is released from the mitochondria during apoptosis. AIF and endonuclease G are caspase-independent proteins that translocate to the nucleus and cause DNA fragmentation. Nuclear condensation in this state, called “stage I” condensation, and caspase-dependent proteins that are cleaved by caspase-3
produce advanced chromatin condensation, called “stage II” condensation [40, 41]. We have summarized the major intrinsic pathway proteins, along with their common abbreviations, and have stated their roles in Table 3.

### Table 3 Some of the proteins involved in the mitochondrial pathway, along with their roles and abbreviations

| Abbreviation(s) | Full name(s) | Role(s) |
|-----------------|--------------|---------|
| AIF             | Apoptosis inducing factor | Induces apoptosis in a caspase-independent death effector manner |
| Apaf-1          | Apoptotic protease activating factor | Creates an apoptosome as a key mediator of the intrinsic pathway |
| Bcl-2, Bcl-10   | B-cell lymphoma protein 2, 10 | Acts as a pro- or anti-apoptotic protein and regulates the release of cytochrome C from the mitochondria |
| BAD             | Bcl-2 antagonist of cell death | Acts as a pro-apoptotic protein |
| BAG             | Bcl-2 associated athanogene | Enhances the anti-apoptotic effects of BCL2 and represents a link between growth factor receptors and anti-apoptotic mechanisms |
| BAK             | Bcl-2 antagonist killer 1 | Permeabilizes the mitochondrial outer membrane during the mitochondrial pathway |
| BAX             | Bcl-2 associated X protein | Forms a heterodimer with BCL2 and functions as an apoptotic activator |
| Caspase-9       | Cysteiny1 aspartic acid-protease-9 | Activates caspase-3, -6 and -7 and initiates a caspase cascade |
| IAP             | Inhibitor of apoptosis proteins | Inhibits the activation of caspase 3,7,9 |
| CAD             | Caspase-activated DNAse | Degrades DNA during apoptosis, as well as its inhibitor ICAD |
| BID             | BH3 interacting domain death agonist | Induces apoptosis via insertion of Bax into organelle membranes |
| BIK             | Bcl-2 interacting killer | Induces apoptosis and acts as target for anti-apoptotic proteins |
| BIM             | Bcl-2 interacting protein | Enhances the anti-apoptotic effects of Bcl-2 |
| Blk             | Bik-like killer protein | Is a pro-apoptotic member of the Bcl-2 family |

3. *Nigella sativa*

*N. sativa* (family: Ranunculaceae) is a medicinal plant popularly called by different names, such as black seed, black cumin, and the seed of blessing (Habatul-barakah in Arabic) [42]. *N. sativa* is a 20- to 90-cm-tall bisexual plant that grows mainly in parts of Asia such as the Middle East and in southern Europe and northern Africa. Its blue solitary flowers are on long peduncles. When the fruit capsule forms, it consist of many white trigonal seeds that turn black in color when the fruit has matured and opened, exposing the black seeds to air [43, 44]. The seeds and oil of *N. sativa* are the main parts of the plants that have been used for medicinal purposes for thousands of years [45, 46].

### 3.1. Chemical composition of *Nigella sativa*

A wide range of chemical compounds found in *N. sativa* express its vast therapeutic effects. Thymoquinone (TQ) is the main component (up to 50%) in the essential oil of *N. sativa*. Also, pinene (up to 15%), p-cymene (40%), thymohydroquinone (THQ), thymol (THY), and dithy- moquinone (DTQ) are other pharmacologically active compounds of its oil. Other terpenoid compounds, such as carvacrol, carvone, 4-terpineol, limonenes, and citronellol, are also found in small quantities in its oil [47]. In addition to the volatile oil (0.5% - 2.5%), fixed oil (35.6% - 41.6%), proteins (22.7%), amino acids, mucilage, reduced sugars, tannins, organic acids, resins, glycosidal saponins, moisture, and Arabian acid are present. Two different types of alkaloids (isoquinoline alkaloids such as nigellicin and pyrazole[1] alkaloids) are found in the seeds [48]. Black cumin seeds contain unsaturated fatty acids [e.g., eicosadienoic[3] acid (3%), oleic acid (20%), dihomolinoleic acid (10%), and linoleic acid (55%)] and sat-
urated fatty acids (e.g., stearic acid (3%) and palmitic acid (14%)). The seeds have also been found to contain crude fiber, vitamins, such as ascorbic acid, thiamine, niacin, pyridoxine, and folic acid, and minerals, such as Fe, Na, Cu, Zn, P, and Ca [49]. Moreover, free sterols, steryl glucosides, acylated steryl glucosides, and steryl esters have been isolated from the seed oil [50, 51]. β-carotene (pro-vitamin A) and tocopherol derivatives, as well as phytosterols, such as β-sitosterol, and in smaller amounts, Δ5-avenasterol, Δ7-avenasterol, campesterol, stigmasterol, and lanosterol, have been identified in black cumin seed oil [48]. The major phospholipid classes include phosphatidylcholine, phosphatidylyserine, phosphatidylethanolamine, and phosphatidylinositol [52].

4. Traditional Uses and Pharmacological Properties of *N. sativa*

Historical and religious uses of *N. sativa* go back to antiquity. In ancient written sources, it is referred to as the melanthion (literally meaning little black seed) of Hippocrates and Dioscorides and as the ghist of Pliny [53]. In the Bible, it is referred to as "the curative black cumin", and the prophet Mohammed described it as a plant with amazing healing powers [54, 55]. Treatments of fever, the common cold, asthma, rheumatic diseases, warts, headache, scorpion stings, and snake bites are examples of ancient applications of black cumin in folk medicine in the Middle and Far East. Ancient Egyptian and Greek physicians also used black cumin to treat nasal congestion, toothaches, and intestinal worms; they also used it as a diuretic and galactagogue. More recently, *N. sativa* has been used to treat infections, pain, obesity, hypertension, and gastrointestinal problems [56-62]. The seeds have also been used externally for many years to treat eczema, abscesses, nasal ulcers, seizures, orchitis, and rheumatism [62-66]. The stimulant, aromatic and carminative properties of *N. sativa*, as well as its beneficial effects in the treatment of patients with diarrhea, indigestion, loss of appetite, dysmenorrhea, and amenorrhea are the most important indications of this plant from the past to now [45, 47, 67].

Recent studies on the pharmacological properties of *N. sativa* have shown that the plant and its active constituent TQ have many beneficial effects, including anti-nociceptive, hypotensive, uricosuric, choleric, anti-fertility, anti-histaminic, immune stimulating, hypoglycemic, hepatoprotective, neuroprotective, spasmytotic, milk production, anti-tussive, and bronchodilator effects [45, 59, 68-80]. The anti-inflammatory, antioxidant, and apoptotic actions of *N. sativa* are the main mechanisms leading to its beneficial health effects [44, 45, 74, 81-83].

5. *N. sativa* and Apoptosis

Due to the indiscriminate and immoderate use of drugs and to their costs, side effects, and interactions, medicinal plants seem to have become appropriate alternatives for use in treating patients with diseases because of their availability and low costs; they also have fewer drug interactions. Currently, many medicinal plants have been found to possess remarkable beneficial properties with different mechanisms [3-5]. The mechanism of apoptosis is a novel therapeutic approach in the treatment of different diseases, especially cancer [84]. Recent scientific studies on plants used in ethn medicine have led to the finding of many beneficial anticancer drugs, such as navelbine, vincristine, taxol, camptothecin, and so forth. [85, 86]. In the following subsections, we discuss the pharmacotherapy and the role of *N. sativa* as a valuable medicinal plant and the effects of its active compounds on various body systems.

5.1. *N. sativa* Effects on Apoptosis in *in vitro* Studies

As mentioned, *N. sativa* has been traditionally used as a tonic to prevent diseases and promote health [88]. *N. sativa* and its active compounds have also been shown to have possible anti-tumor activities. For many years, an extract of *N. sativa* seeds, *Smilax glabra* (rhizome) and *Hemidesmus indicus* (root), has been used for the treatment of cancer in Sri Lanka [88].

A recent study investigated the anti-cancer effect of *N. sativa* seeds, *Smilax glabra* (rhizome) and *Hemidesmus indicus* (root) extracts and reported that the greatest inhibitory effects on DNA synthesis were observed with *N. sativa* plant extract (88 ± 3.8%) even at low concentrations (5 mg/mL) [89]. Shafi et al. showed that melanthonic, n-Hexane, and chloroform extracts of *N. sativa* were capable of killing human cervical carcinoma (HeLa) cells and that the IC50 values were 2.28 μg/mL, 2.20 μg/mL, and 0.41 ng/mL, respectively. In that study, the occurrence of apoptosis in HeLa cells was confirmed by using DNA fragmentation, western blot analyses, and terminal transferase mediated dUTP-digoxigenin-end labeling (TUNEL) assays. Based on their observations, the authors concluded that the expressions of pro- and anti-apoptotic genes were regulated by the extracts, indicating *N. sativa* to be a potential therapeutic medicinal plant for use in the treatment of patients with cervical cancer [90].

Hasan et al. reported the potential anti-cancer effects of *N. sativa* extract on human cervical cancer cells (SiHa) (88.3% inhibition, IC50 = 93.2 μL/mL) due to the expressions of caspase-3, -8 and -9 being increased several-fold [91]. Samarakoon et al. in their study showed that the extract could up-regulate the expression of the pro-apoptotic gene Bcl2-associated X protein, down-regulate the expression of the anti-apoptotic Bcl-2 gene, and enhance the activities of caspase-3 and caspase-9 in a time- and dose-dependent manner [92]. In another study, the impact of *N. sativa* on the growth of HeLa cells was investigated [93]. In that study, the apoptotic function of the ethanol extract was found to be associated with the release of mitochondrial cytochrome C, an increase in the Bax/Bcl-2 ratio, activations of caspases-3, -9 and -8, cleavage of PARP, increased expressions of p53 and p21, and decreased expressions of oncoproteins (c-Myc), human telomerase reverse
transcriptase (hTERT), cyclin D1, and cyclin-dependent kinase-4 (CDK-4). The results of that study were confirmed by Shahraki et al. in a separate study done on human renal adenocarcinomas and normal renal epithelial cells [94]. Shioeib et al. showed that TQ, the most abundant constituent present in *N. sativa*, was responsible for in vitro inhibition of growth and induction of apoptosis in cancer cell lines [95]. In that study, TQ (25 μM) induced apoptosis of COS31 (canine osteosarcoma) cells 6 h after treatment, decreased the number of COS31 cells in the S-phase, and increased the number of cells in the G1-phase, indicating cell-cycle arrest at G1. The results of that study suggest that TQ kills cancer cells through a process that involves apoptosis and cell-cycle arrest. Gali-Muhtasib *et al.* reported a similar result with a different mechanism for *N. sativa* [96].

They showed that TQ triggered human colorectal cancer cells via a p53-dependent mechanism (2.5- to 4.5-fold increase in mRNA expression of p53) and a significant inhibition of the anti-apoptotic Bcl-2 protein. Furthermore, using the TUNEL method and a flow cytometry analysis, they demonstrated that TQ inhibited the growth of colon cancer cells, which correlated with G1-phase arrest of the cell cycle, in a dose- and time-dependent manner. Thus, that study supports the potential use of the agent TQ for the treatment of patients with colon cancer.

Arafat *et al.* reported that TQ greatly inhibited doxorubicin-resistant human breast cancer (MCF-7/DOX) cell proliferation through the following mechanisms: increases in the cellular levels of phosphatase and tensin homolog (PTEN) proteins and elevation of PTEN mRNA, resulting in a substantial decrease in the level of phosphorylated Akt (a known regulator of cell survival), increases in cellular levels of p53 and p21 proteins, an increase in the sub-G1 cell population, disruption of the mitochondrial membrane potential, activation of caspases, PARP cleavage, and an increase in the Bax/Bcl2 ratio via up-regulating Bax and down-regulating Bcl2 proteins. These results provide mechanistic insights for understanding the beneficial effects of TQ. Treating p53-null myeloblastic leukemia (HL-60) cells with TQ was found to trigger the activation of caspases -8, -9 and -3 and to cause a significant increase in the Bax/Bcl2 ratio due to up-regulation of Bax and down-regulation of Bcl2 proteins; these findings indicate that TQ may be a potential agent for the treatment of patients with cancer [97].

TQ was shown to exhibit an anti-proliferative effect, induce apoptosis, disrupt the mitochondrial membrane potential, and trigger the activations of caspases -8, -9 and -3 in HL-60 cells [98]. Gali-Muhtasib *et al.* by using primary mouse keratinocytes, papilloma (SP-1) cells, and spindle (I7) carcinoma cells reported that non-cytotoxic concentrations of TQ could reduce the proliferation of neoplastic keratinocytes by 50%. The sensitivity of the cells to TQ treatment appeared to be stage-dependent, such that papilloma cells were twice as sensitive to the growth inhibitory effects of TQ as the spindle cancer cells. TQ treatment of SP-1 caused G0/G1 cell-cycle arrest, an increase in the expression of the cyclin-dependent kinase inhibitor p16, and a decrease in cyclin D1 protein expression. Also, TQ treatment of I7 induced G2/M cell-cycle arrest, increased the expression of the tumor suppressor protein p53, and decreased the expression of cyclin B1 protein. That study showed that the apoptotic effects of TQ were more pronounced in SP-1 than in I7 cells. Therefore, the findings support a potential role for TQ as a chemopreventive agent [99].

In Rooney and Ryan’s study, the effects of TQ on four human cancer cell lines (A549 (lung carcinoma), HT-29 (colon adenocarcinoma), HeLa (larynx epidermoid carcinoma) and MIA PaCa-2 (pancreas carcinoma)) were investigated. They reported that TQ induced a dose- and time-dependent apoptotic effect on the cell lines tested and that Hep-2 cells were the most sensitive to TQ [100]. In a similar study by them on Hep-2 cells treated with TQ, glutathione levels were significantly decreased in a dose-dependent manner and caspase-3-activation was mediated [101]. Sethi *et al.* reported that treatment with TQ suppressed TNF-induced NF-κB activation in a dose- and time-dependent manner and inhibited NF-κB activation (correlated with the inhibition of the activation of IκB, IκB phosphorylation, IκB degradation, p65 phosphorylation, p65 nuclear translocation, and NF-κB-dependent reporter gene expression) induced by various carcinogens and inflammatory stimuli. TQ also down-regulated the expressions of NF-κB-regulated anti-apoptotic (IAP1, IAP2, XIAP Bcl-2, Bcl-XL, and survivin), proliferative (cyclin D1, cyclooxygenase-2, and c-Myc), and angiogenic (matrix metalloproteinase-9 and vascular endothelial growth factor) gene products. Overall, TQ may play the lead role in the apoptotic effects of TQ in the treatment of patients with cancer [102]. Ng *et al.* in their study reported that TQ was more influential compared to cisplatin in eliminating SiHa. Treatment with TQ in the cells showed a significant elevation of p53 and a down-regulation of Bcl-2 (anti-apoptotic protein) in the treated cells without any changes in the expression of the Bax protein in a dose-dependent manner [103].

The cytotoxicity and the anti-proliferative effects of TQ towards HeLa were investigated [104]. The authors of that study reported that TQ exhibited time-dependent cytotoxic and anti-proliferative activities towards the cells with IC50 values of 2.80 ± 0.10 mg/mL and 5.37 ± 0.12 mg/mL, respectively. The proposed mechanism for this activity was via the p53-dependent pathway. Harzallah *et al.* reported that the apoptotic effects of TQ on Hep-2 cell lines (IC50 = 19.25 ± 1.60 μg/mL) were remarkably more potent than those of the essential oil of *N. sativa* (IC50 = 55.20 ± 2.10 μg/mL) [105].

TQ can affect cancer cell lines through different mechanisms. Kundu *et al.* reported that TQ remarkably diminished the viability of human colon cancer cells (HCT116) in a concentration- and time-dependent manner. The proposed mechanisms of that study were up-regulation of Bax, inhibitions of Bcl-2 and Bcl-XL expressions, activations of caspase-9, -7, and -3, activation of PARP cleavage, inhibited constitutive phosphorylation, nuclear localization and reporter gene activity of the signal transducer and the activator of transcription-3 (STAT-3), attenuations of the expressions of STAT-3 target gene products, such as survivin, c-Myc, and cyclin-D1. *D2*, enhanced expressions of cell-cycle inhibitory proteins p27 and p21, and attenuations of the phosphorylation of upstream kinases, such as Janus-activated kinase-2 (JAK2), Src kinase, and
| Cancer cell line(s) | Roles of apoptosis | Reference |
|-------------------|-------------------|-----------|
| Human renal adenocarcinoma and normal renal epithelial | Bcl2 is under-expressed, P53 is over-expressed, and caspases 3, 8, and 9 are activated. | 94 |
| Human colon cancer cells (Caco-2, HCT-116, LoVo, DLD-1 and HT-29) | Apoptosis was induced via the generation of ROS. TQ increased the phosphorylation states of the MAPK, JNK and ERK. | 117 |
| Fibrosarcoma (HT1080) | NSO produced a concentration-dependent inhibition of t-PA, u-PA and PAI-1. Plasminogen activation system (modulation of the fibrinolytic potential of fibrosarcoma) is depleted. | 118 |
| Squamous cell carcinoma (SCC VII) and fibrosarcoma (FsaR) | RNA expression of p53 and the downstream p53 target gene inhibition of anti-apoptotic Bcl-2 is increased several fold. | 119 |
| HL-60 cells | Apoptosis is induced by activating caspase-3 and 8. | 120 |
| PC3 | Cell proliferation is inhibited by TQ, and the activations of AKT and extracellular signal-regulated kinase are suppressed. Vascular endothelial growth factor–induced extracellular signal–regulated kinase activation is inhibited. Acts as an angiogenesis inhibitor. | 121 |
| Human multiple myeloma cells | Both constitutive and IL-6-inducible STAT3 phosphorylation, which correlated with the inhibitions of c-Src and JAK2 activations, are inhibited. Signal transducer and activator of the transcription 3 activation pathway is suppressed. | 122 |
| Human lung cancer cell line | Cell viability is reduced and the cellular morphology of A-549 cells is altered in a concentration-dependent manner. | 123 |
| Osteosarcoma (SaOS-2) | TQ significantly blocked human umbilical vein endothelial cell tube formation in a dose-dependent manner. TQ significantly downregulated NF-κB DNA-binding activity, XIAP, survivin and VEGF. Expressions of cleaved caspase-3 and Smac were upregulated in SaOS-2 cells. NF-κB and its regulated molecules and anti-angiogenesis effects are suppressed. | 124 |
| Primary effusion lymphoma (PEL) cell lines | Constitutive activation of AKT via generation of ROS is downregulated and conformational changes in Bax protein, leading to the loss of mitochondrial membrane potential and the release of cytochrome c to the cytosol, are caused. Caspase-9, caspase-3, and polyadenosine 5′-diphosphate ribose polymerase cleavage are activated, leading to caspase-dependent apoptosis. TQ is a potent inducer of apoptosis in PEL cells via release of ROS. | 125 |
| Hepatic stellate cells | TQ significantly attenuated the expression of CD14 and Toll-like receptor 4. TQ also significantly inhibited phosphatidylinositol 3-kinase and serine/threonine kinase–protein kinase B phosphorylation. Expressions of α-SMA and collagen-I were significantly decreased by TQ. TQ decreased XIAP and cellular FLIP expression, which are related with the regulation of apoptosis. | 126 |
epidermal growth factor receptor (EGFR) tyrosine kinase. Therefore, TQ exhibited apoptotic effects mainly by blocking STAT-3 signaling via inhibition of Src and JAK2 [106]. Also, different mechanisms of TQ, such as activation of glycogen synthase kinase-3, an increase in the membrane localization of β-catenin, a reduction in the nuclear expression of c-myc [107], reductions in the expressions of tumor markers (PCNA, Ki67, cyclin D1, cyclin E, and Cdk4), an increase in the expression of p21, and down-regulation of the Bcl-2 protein [108], were also shown. Reductions in the expressions of XIAP, Bcl-2, Bcl-xL, and survivin, an increase in the phosphorylation of p38 mitogen-activated protein kinase (MAP) [109], reductions in the expressions of AR, E2F1 and cyclin A [110], inhibition of MEK-ERK1/2 signaling and disruption of its pro-survival function and pERK1/2 loss [111], and a blocking of the PI3K/Akt signaling pathway [112] are the other reported anti-cancer mechanisms of TQ.

Ait Mbarek et al. evaluated the in vitro anti-cancer effect of *N. sativa* [85]. Their findings showed that the essential oil and the ethyl acetate extracts of *N. sativa* were more cytotoxic than the butanol extracts against the murine mastocytoma cell line (P815), a result similar to that for the kidney carcinoma cell line of monkeys (Vero). As a result, the data showed that the effect of each extract depended on the tumor cell type. Another study showed that an aqueous extract of *N. sativa* significantly enhanced natural killer cytotoxic activity against mouse lymphoma cells (YAC-1) [113]. The effects of TQ on the colon cancer (HT29), lymphoblastic leukemia (CEMSS), and promyelocytic leukemia (HL60) cell lines were investigated [115], and the IC50 values of TQ were found to be 8, 5 and 3 μg/mL, respectively, and those values were found to behave in a time-dependent manner. Although TQ could not arrest the cell-cycle phases of the cells, apoptosis was the main mode of HT29 and HL60 cell death induced by TQ [114].

Another agent isolated from *N. sativa* is a-hederin, has been reported to have a potent antitumor effect, as well. Swamy and Haut reported a dose- and time-dependent increase in the apoptosis of murine leukemia (P388) cells, with the mechanism being the release of cytochrome C from the mitochondria to cytosol, leading to caspase-3 activation [115]. Thus, the findings of that study provide a mechanism of a-hederin-induced cell death caused by changes in intracellular thios and the redox status, leading to perturbations of mitochondrial functions.

The anti-inflammatory effects of TQ on pancreatic ductal adenocarcinoma cells (PDA) were investigated by Chehl et al. [116]. The effects of TQ on the expressions of different pro-inflammatory cytokines and chemokines, which were analyzed by using the real-time polymerase chain reaction (PCR), showed significant reductions in PDA cell syntheses of MCP-1, TNF-α, IL-1β and COX-2 in a dose-dependent manner. TQ also inhibited the TNF-α-mediated activation of NF-κB in PDA cells and reduced the transport of NF-κB from the cytosol to the nucleus. Thus, the use of TQ may be a promising strategy for inhibiting pro-inflammatory pathways [116].

Table 4 provides a summary of the results of studies that showed *N. sativa* could have an effect on cancer cell lines. The table lists the cell lines and the roles of *N. sativa* in the mechanism of apoptosis.

### 5.2. *N. sativa* Effects on Apoptosis in *in vivo* Studies

The published findings provide much information about the anti-tumor effects of *N. sativa*, particularly in *in vivo* studies. Ait Mbarek et al reported that in the DBA2/P815 (H2d) mouse model, a meaningfully inhibition of solid tumor development was found when the essential oil of *N. sativa* was injected into the tumor site. When 30 μL (28.5 mg)/mouse and 50 μL (47.5 mg)/mouse of the essential oil were injected in the tumor every 48 h for six times, the tumor volumes of animals (2.5 ± 0.6 cm3) were reduced 0.22 ± 0.1 and 0.16 ± 0.1 cm3, respectively. In addition, the incidence of metastasis of the liver was suppressed by the administration of the essential oil into the tumor site, and the mouse’s survival was increased [85].

Another study reported that *N. sativa* had a protective effect against mammary carcinomas induced by 7, 12-dimethylbenz (a) anthracene (DMBA) [128]. In that study, administration of *N. sativa* for 3 months was associated with decreased levels of markers of apoptotic activity (29.0 ± 1.7 vs. 20.9 ± 1.3 and P < 0.05 for the percentage of DNA fragmentation; 20.8 ± 1.1 vs. 13.4 ± 0.7 and P < 0.01 for caspase-3; and 9.4 ± 0.8 vs. 52.1 ± 3.3 and P < 0.01 for TNF-α). Therefore, *N. sativa* decreased the carcinogenic effects of DMBA, suggesting a protective role against cancer.

The chemo-preventive activity of *N. sativa* oil against rat colon carcinomas was evaluated in the model of 1, 2-dimethylhydrazine-induced aberrant crypt foci (ACF: clusters of abnormal tube-like glands in the lining of the colon and rectum in rats) [129]. The findings of that study showed that the oil of *N. sativa* had the ability to inhibit colon carcinogenesis with no evident adverse side effects and that the inhibition may be associated, in part, with the suppression of cell proliferation in the colonic mucosa. Lei et al. reported that in the xenograft tumor mouse model for the treatment of gastric cancer, the combination of TQ/5-
FU induced apoptosis via activations of caspase-3 and -9 [130].

Modulation of inducible nitric oxide synthase (iNOS) pathway suppression of the inflammatory response mediated by TNF-α and IL-6 may be effective in the treatment of patients with a hepatocellular carcinoma by using *N. sativa* [131]. A combination of TQ and cisplatin in the treatment of lung cancer in a mouse xenograft model showed that TQ was able to inhibit cell proliferation (nearly 90%), reduce cell viability, induce apoptosis, and reduce tumor volume and tumor weight. As a result, TQ can regulate NF-κB expression and act with synergism activity with cisplatin. Therefore, TQ appears to be have active therapeutic potential for the treatment of patients with cancer [132].

The anti-proliferative and pro-apoptotic effects of TQ in the breast-tumor xenograft mouse model are mediated by p38 phosphorylation via ROS generation and potentiate the antitumor effect of doxorubicin [109]. Another study showed that the administration of TQ (10 mg/kg/i.p.) for 18 days inhibited lung cancer (LNM35) tumor growth by 39% (*P* < 0.05); this was associated with a remarkable increase in the expression of activated caspase-3 [133]. Hence, based on these experimental findings, we conclude that TQ has clinical potential as an anticancer agent.

Salim in his study reported that post-initiation administration of 1,000 or 4,000 ppm *N. sativa* volatile oil in the diet of male rats for 30 weeks remarkably reduced the incidences of benign and malignant colon tumor and their sizes, especially those in the lungs, murine colon, esophagus, and forestomach [134]. This finding shows the potent inhibitory effects on rat cellular proliferation and tumor development in multiple organ sites. Kundu *et al.* reported that the pretreatment of hairless mouse skin with TQ attenuated 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of COX-2 and the phosphorylations of Akt, c-Jun-N-terminal kinase, and p38 MAPK [135]. It also diminished nuclear translocation and the DNA binding of NF-κB by blocking the phosphorylation and subsequent degradation of IκB. Fig. 2 shows the roles of apoptosis in cancer treatment using *N. sativa*.

6. Conclusion

Due to the increased worldwide popularity, safety, and low cost of medicinal plants, their uses to treat patients...
with disorders ranging from simple ailments to more complex ones such as cancer are on the rise. The published findings show that *N. sativa*, especially TQ its predominant bioactive constituent, shows anticancer properties with apoptotic effects; for that reason, it can be used to treat patients with various diseases and disorders, especially cancer. Induction of apoptosis by TQ was shown through the up-regulation of p21 and p53, together with the inhibition of Bcl-2, the activations of caspases -8, -9 and -3, and increases in the Bax/Bcl-2 ratio. Up-regulation of tumor suppressors, along with a decrease in p-Akt, is another apoptotic effect of TQ. TQ was shown to suppress IAP1, IAP2, Bcl-2, Bcl-xl, XIAP, survivin, COX-2, cyclin D1, and VEGF as NF-κB-regulated gene products due to its inhibitory effects on TNF-α. Inhibition of both VEGF-dependent ERK and Akt activation are other anti-cancer mechanisms of *N. sativa*.

These results are important because they highlight the potential effects of *N. sativa* in the treatment of patients with cancer; thus encouraging researchers to conduct further studies in order to develop various and more effective formulations to treat an array of diseases, including cancer. Lately, *N. sativa* has become an important topic for research worldwide, but more studies need to be done to discover the different apoptotic mechanisms that further show the therapeutic efficiency of the plant against cancer.

**Conflict of interest**

The authors declare that they have no conflicts of interest.

**References**

1. Grundy SM. Recent nutrition research: implications for foods of the future. Ann Med. 1991;23(2):187-93.

2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, *et al*. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-71.

3. Dirin MM, Mousavi S, Afshari AR, Tabrizian K, Ashrafi MH. Potential drug-drug interactions in prescriptions dispensed in community and hospital pharmacies in East of Iran. J Res Pharm Pract. 2014;3(3):104-7.

4. Afshari AR, Sadeghnia HR, Mellazadeh H. A review on potential mechanisms of *Terminalia chebula* in Alzheimer’s disease. Adv Pharmacol Sci. 2016;2016.DOI: 8964849.

5. Afshari AR, Boroushaki MT, Mellazadeh H. Pomegranate seed oil: a comprehensive review on its therapeutic effects. IJPSR. 2016;7(2):1000-13.

6. Sadeghnia HR, Jamshidi R, Afshari A, Mellazadeh H, Forouzanfar F, RashshandeH. *Terminalia chebula* attenuates quinolinate-induced oxidative PC12 and OLN-93 cells death. Mult Scler Relat Disord. 2017;14:60-7.

7. Mellazadeh H, Boroushaki MT, Soukhstanloo M, Afshari AR, Vahedi MM. Effects of pomegranate seed oil on oxidant/antioxidant balance in heart and kidney homogenates and mitochondria of diabetic rats and high glucose- treated H9c2 cell line. Avicenna J Phytomed. 2017;7(4):317-33.

8. Spencer DS, Puranik AS, Peppas NA. Intelligent nanoparticles for advanced drug delivery in cancer treatment. Curr Opin Chem Eng. 2015;7:84-92.

9. Lee YW, Chen TL, Shih YR, Tsai CL, Chang CC, Liang HH, *et al*. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer. 2014;120(9):1338-44.

10. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485-95.

11. Khan MA, Chen HC, Tania M, Zhang DZ. Anticancer activities of *Nigella sativa* (black cumin). Afr J Tradit Complement Altern Med. 2011;8(S5):226-32.

12. Lo AC, Woo TT, Wong RL, Wong D. Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica. 2011;226:10-7.

13. Carson DA, Ribeiro JM. Apoptosis and disease. The Lancet. 1993;341(8855):1251-4.

14. Mousavi S H, Tayarani Najaran Z, Hersey P. Apoptosis: from signalling pathways to therapeutic tools. Iranian J Basic Med Sci. 2008;11(3):121-42.

15. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.

16. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267(5203):1445-9.

17. Mousavi SH, Hersey P. Role of caspases and reactive oxygen species in rose Bengal-induced toxicity in melanoma cells. Iranian J Basic Med Sci. 2007;10(2):118-23.

18. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-57.

19. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res. 2000;45(3):528-37.

20. Kurosaka K, Takahashi M, Watanabe N, Kobayashi Y. Silent cleanup of very early apoptotic cells by macrophages. J Immunol. 2003;171(9):4672-9.

21. Gregory CD, Devitt A. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?. Immunology. 2004;113(1):1-14.

22. Ihara T, Yamamoto T, Sugamata M, Okumura H, Ueno Y. The process of ultrastructural changes from nuclei to apoptotic body. Virchows Arch. 1998;433(5):443-7.

23. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407(6805):784-8.

24. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770-6.

25. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, *et al*. Human ICE/CED-3 protease nomenclature. Cell. 1996;87(2):171.

26. Ihara T, Yamamoto T, Sugamata M, Okumura H, Ueno Y. The process of ultrastructural changes from nuclei to apoptotic body. Virchows Arch. 1998;433(5):443-7.

27. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407(6805):784-8.

28. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, *et al*. Human ICE/CED-3 protease nomenclature. Cell. 1996;87(2):171.

29. Nicholson DW, Thornberry NA. Caspases: killer proteases. Nature. 2000;407(6805):770-6.

30. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, *et al*. Human ICE/CED-3 protease nomenclature. Cell. 1996;87(2):171.

31. Nicholson DW, Thornberry NA. Caspases: killer proteases. Nature. 2000;407(6805):770-6.
Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2000;2(6):318-25.
30. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305-8.
31. Igney FH, Kramer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2(4):277-88.
32. Wajant H. The Fas signaling pathway: more than a paradigm. Science. 2002;296(5573):1305-8.
33. Sullivan A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene. 2001;20(17):2122-33.
34. Scaffidi C, Schmitz I, Kramer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999;274(3):1541-8.
35. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graebe T, et al. Cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenic role in eczematous dermatitis. J Clin Invest. 2000;106(1):25-35.
36. Fulda S, Debatin KM. Extrinsc versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798-811.
37. Saelens X, Festjens N, Walle IV, Van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23(16):2861-74.
38. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006;13(9):1423-33.
39. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621-32.
40. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med. 2000;192(4):571-80.
41. Iglesias-Guinarais V, Gil-Guion E, Sanchez-Osuna M, Casanelles E, Garcia-Belinchón M, Comella JX, et al. Chromatin collapse during caspase-dependent apoptotic cell death requires DNA fragmentation factor, 40-kDa subunit-/caspase-activated deoxyribonuclease-ase-mediated 3′-OH single-strand DNA breaks. J Biol Chem. 2013;288(13):9200-15.
42. Halawani E. Antibacterial activity of thymoquinone and thymohydroquinone of Nigella sativa L. and their interaction with some antibiotics. Adv Biol Res. 2009;3(5-6):148-52.
43. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337-52.
44. Hosseinzadeh H, Parvardeh S, Asl MN, Sadeghnia HR, Ziaee T. Effect of thymoquinone and Nigella sativa seeds oil on lipid peroxidation level during global cerebral ischemia-reperfusion injury in rat hippocampus. Phytomedicine. 2007;14(9):621-7.
45. Mollazadeh H, Hosseinzadeh H. The protective effect of Nigella sativa against liver injury: a review. Iran J Basic Med Sci. 2014;17(12):958-66.
46. Hosseinzadeh H, Parvardeh S. Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomedicine. 2004;11(1):56-64.
47. El-Tahir KE-DH, Bakeet DM. The black seed Nigella sativa Linnaeus—a mine for multi cures: a plea for urgent clinical evaluation of its volatile oil. J Taibah Univ Sci. 2006;1(1):1-19.
48. Ramadan ME. Nutritional value, functional properties and nutraceutical applications of black cumin (Nigella sativa L.): an overview. Int J Food Sci Tech. 2007;42(10):1208-18.
49. Ziaee T, Moharreri N, Hosseinzadeh H. Review of pharmacological and toxicological effects of Nigella sativa and its active constituents. J Med Plants. 2012;2(42):16-42.
50. Ramadan ME, Moersel JT. Analysis of glycolipids from black cumin (Nigella sativa L.), coriander (Coriandrum sativum L.) and niger (Guizotia abyssinica Cass.) oilseeds. Food Chem. 2003;80(2):197-204.
51. Boskabady MH, Vahedi N, Amery S, Khakzad MR. The protective effect of Nigella Sativa alone and in combination with dexamethasone on tracheal responsiveness and lung inflammation of sulphur mustard exposed guinea pigs. J Ethnopharmacol. 2011;137(2):1028-34.
52. Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.). J Pharm Biomed. 1999;19(5):757-62.
53. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005;5(13-14):1749-70.
54. Sahebkar A, Soranna D, Liu X, Thomopoulos C, Simental-Mendia LE, Derosa G, et al. A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. J Hypertens. 2016;34(11):2127-35.
55. Boskabady MH. Physio-pathological characteristics of sulfur mustard exposed human and guinea pigs and the possible therapeutic interventions. Iranian Congress Physiol Pharmacol. 2009;19.
56. Yarnell E, Abascal K. Nigella sativa: holy herb of the middle East. Alternative and Complementary Therapies. 2011;17(2):99-105.
57. Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH. From here to eternity - the secret of Pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther. 2008;6(b):495-510.
58. Abdel-Sater KA. Gastroprotective effects of Nigella Sativa oil on the formation of stress gastritis in hypothyroidal rats. Int J Physiol Pathophysiol Pharmacol. 2009;1(2):143-9.
59. Amin B, Hosseinzadeh H. Black cumin (Nigella sativa) and its active constituent, thymoquinone: an overview on the analgesic and anti-inflammatory effects. Planta Med. 2016;82(1-2):8-16.
60. Vafaee F, Hosseini M, Hassanzadeh Z, Edalatmanesh MA, Sadeghnia HR, Seghatoleslam M, et al. The effects of Nigella sativa hydro-alcoholic extract on memory and brain tissues oxidative damage after repeated seizures in rats. Iran J Pharm Res. 2015;14(2):547-57.
61. Forouzanfar F, Bazzaz BSF, Hosseinzadeh H. Black cumin (*Nigella sativa*) and its constituent (thymoquinone): A review on antimicrobial effects. Iran J Basic Med Sci. 2014;17(12):929-38.
62. Hosseinzadeh H, Fazly Bazzaz BS, Haghi MM. Antibacterial activity of total extracts and essential oil of *Nigella sativa* seeds in mice. Pharmacologyonline. 2007;2:429-35.
63. el-Dakhakhny M. Studies on the Egyptian *Nigella sativa* L. IV. some pharmacological properties of the seeds' active principle in comparison to its dihydro compound and its polymer. Arzneimittelorschung. 1965;15(10):1227-9.
64. Amin B, Taheri MM, Hosseinzadeh H. Effects of intraperitoneal thymoquinone on chronic neuropathic pain in rats. Planta Med. 2014;80(15):1269-77.
65. Hosseinzadeh H, Parvardeh S, Nassiri-Asl M, Mansouri MT. Intracerebroventricular administration of thymoquinone, the major constituent of *Nigella sativa* seeds, suppresses epileptic seizures in rats. Med Sci Monit. 2005;11(4):106-10.
66. Havakhalh S, Sadeghnia HR, Hajzadeh MA, Roshan NM, Shafee S, Hosseinzadeh H, et al. Effect of *Nigella sativa* on ischemia-reperfusion induced rat kidney damage. Iran J Basic Med Sci. 2014;17(12):986-92.
67. Ali BH, Blunden G. Pharmacological and toxicological properties of *Nigella sativa*. Phytother Res. 2003;17(4):299-305.
68. Hosseinzadeh H, Moghim FF, Mansouri SMT. Effect of *Nigella sativa* seed extracts on ischemia-reperfusion in rat skeletal muscle. Pharmacologyonline. 2007;2:326-35.
69. Hosseinzadeh H, Tafaghi M, Mosavi MJ, Taghiabadi E. Effect of aqueous and ethanolic extracts of *Nigella sativa* seeds on milk production in rats. J Acupunct Meridian Stud. 2013;6(1):18-23.
70. Lei X, Liu M, Yang Z, Ji M, Guo X, Dong W. Thymoquinone prevents and ameliorates dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2012;57(9):2296-303.
71. Pourbaksh H, Taghiabadi E, Abnous K, Hariri AT, Hosseini SM, Hosseinzadeh H. Effect of *Nigella sativa* fixed oil on ethanol toxicity in rats. Iran J Basic Med Sci. 2014;17(12):1002-31.
72. Mehri S, Shahi M, Razavi BM, Hassani FV, Hossein-zadeh H. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iran J Basic Med Sci. 2014;17(12):1007-11.
73. Javid S, Razavi BM, Hossein-zadeh H. A review of neuropharmacology effects of *Nigella sativa* and its main component, thymoquinone. Phytother Res. 2016;30(8):1219-29.
74. Darakhshan S, Pour AB, Colagar AH, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmaco Res. 2015;95-96:138-58.
75. Hosseinzadeh H, Eskandari M, Ziaee T. Antitussive effect of thymoquinone, a constituent of *Nigella sativa* seeds, in guinea pigs. Pharmacologyonline. 2008;2:480-4.
76. Hosseinzadeh H, Taiari S, Nassiri-Asl M. Effect of thymoquinone, a constituent of *Nigella sativa* L., on ischemia-reperfusion in rat skeletal muscle. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(5):503-8.
77. Hosseinzadeh H, Montahaei R. Protective effect of *Nigella sativa* L. extracts and thymoquinone, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. Pharmacologyonline. 2007;1:176-89.
78. Razavi BM, Hosseinzadeh H. A review of the effects of *Nigella sativa* L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest. 2014;37(11):1031-40.
79. Tavakkoli A, Ahmad A, Razavi BM, Hosseinzadeh H. Black seed (*Nigella sativa*) and its constituent thymoquinone as an antidote or a protective agent against natural or chemical toxicities. Iran J Pharm Res. 2017;16:2-23.
80. El Mezayen R, El Gazzar M, Nicolls MR, Marecki JC, Dreskin SC, Nomiyama H. Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett. 2006;106(1):72-81.
81. Umar S, Zargar J, Umar K, Ahmad S, Katiyar CK, Khan HA. Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chem Biol Interact. 2012;197(1):40-6.
82. Javid S, Razavi BM, Hossein-zadeh H. A review of neuropharmacology effects of *Nigella sativa* and its main component, thymoquinone. Phytother Res. 2016;30(8):1219-29.
83. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol. 1999;187(1):127-37.
84. Ait Mbarek L, Ait Mouse H, Elabbadi N, Bensalah M, Gamouh A, Aboufatima R, et al. Anti-tumor properties of blackseed (*Nigella sativa*) L. extracts. Braz J Med Biol Res. 2007;40(6):839-47.
85. Asadi-Samani M, Kooti W, Aslani E, Shirzad H. A systematic review of Iran's medicinal plants with anticancer effects. J Evid Based Complementary Altern Med. 2015;21(2):143-53.
86. Sharma NK, Ahirwar D, Jhade D, Gupta S. Medicinal and pharmacological potential of *Nigella sativa*: a review. Ethnobotanical Leaflets. 2009;13:946-55.
87. Samarakoon SR, Thabrew I, Galhena PB, De Silva D, Tennekoon KH. A comparison of the cytotoxic potential of standardized aqueous and ethanolic extracts of a polyherbal mixture comprised of *Nigella sativa* (seeds), *Hemidesmus indicus* (roots) and *Smilax glabra* (rhizome). Pharmacognosy Res. 2010;2(6):335-42.
88. Thabrew MI, Mitry RR, Morsy MA, Hughes RD. Cytotoxic effects of a decoction of *Nigella sativa*, *Hemidesmus indicus* and *Smilax glabra* on human hepatoma HepG2 cells. Life Sci. 2005;77(12):1319-30.
89. Shafi G, Munshi A, Hasan TN, Alshatiw AA, Jothy A, Lei D. Induction of apoptosis in HeLa cells by chloroform fraction of seed extracts of *Nigella sativa*. Cancer Cell Int. 2009;9:29.
90. Hasan TN, Shafi G, Syed NA, Alawaz MA, Alsaiif MA, Munshi A, et al. Methanolic extract of *Nigella sativa* seed inhibits SiHa human cervical cancer cell proliferation through apoptosis. Nat Prod Commun.
Thymoquinone inhibits proliferation and induces apoptosis in human cervical carcinoma cells. Afr J Biotechnol. 2012;11(64):12710-20.

Shahraki S, Khajavirad A, Shaei MN, Mahmoudi M, Tabasi NS. Effect of total hydroalcoholic extract of Nigella sativa and its n-hexane and ethyl acetate fractions on ACHN and GP-293 cell lines. J Tradit Complement Med. 2015;6(1):89-96.

Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol. 2003;22(1):107-13.

Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p33-dependent mechanism. Int J Oncol. 2004;25(4):857-66.

9Arafa el-SA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res. 2011;706(1-2):28-35.

El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer. 2005;117(3):409-17.

Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N, Crooks PA. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in nonkeratinocyte Anticancer Drugs. 2004;15(4):389-99.

Rooney S, Ryan MF. Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res. 2005;25:2199-204.

Rooney S, Ryan MF. Modes of action of alpha-hederin and thymoquinone, active constituents of Nigella sativa, against HEP-2 cancer cells. Anticancer Res. 2005;25:4255-9.

Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-xB activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008;6(6):1059-70.

Ng WK, Yazan LS, Ismail M. Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Toxicol In Vitro. 2011;25(7):1392-8.

Yazan LS, Ng W, Al-Naqeeb G, Ismail M. Cytoxicity of thymoquinone (TQ) from Nigella sativa towards human cervical carcinoma cells (HeLa). J Pharm Res. 2009;2(4):585-9.

Harzallah HJ, Koudibi B, Flamini G, Bakhrout A, Mahmoud T. Chemical composition, antimicrobial potential against cariogenic bacteria and cytotoxic activity of Tunisian Nigella sativa essential oil and thymoquinone. Food Chem. 2011;129(4):1469-74.

Kundu J, Choi BY, Jeong CH, Kundu JK, Chun KS. Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2-and Src-mediated phosphorylation of EGF receptor tyrosine kinase. Oncol Rep. 2014;32(2):821-8.

Lang M, Borgmann M, Oberhuber G, Evstatiev R, Jimenez K, Dammann KW, et al. Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling. Mol Cancer. 2013;12(1):41.

Raghunandhakumar S, Paramasivam A, Senthilraja S, Naveenkumar C, Asokkumar S, Binuclara J, et al. Thymoquinone inhibits cell proliferation through regulation of G1/S phase cell cycle transition in N- nitrosodiethylamine-induced experimental rat hepatocellular carcinoma. Toxicol Lett. 2013;223(1):60-72.

Woo CC, Hsu A, Kumar AP, Sethi G, Tan KH. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS One. 2013;8(10):e75336.

Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, et al. Androgen receptor–and EZF-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007;67(16):7782-8.

El-Baba C, Mahadevan V, Fahlbsch FB, Mohan S S, Rau TT, Gali-Muhtasib H, et al. Thymoquinone-induced conformational changes of PAK1 interrupt pro-survival MEK-ERK signaling in colorectal cancer. Mol Cancer. 2014;13:201.

Dirican A, Atmaca H, Bozkurt E, Erten C, Karaca B, Uslu R. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Clin Transl Oncol. 2015;17(2):145-51.

Majdalwieh AF, Hmaidan R, Carr RI. Nigella sativa modulates splenocyte proliferation, Th1/Th2 cytokine profile, macrophage function and NK anti-tumor activity. J Ethnopharmacol. 2010;131(2):268-75.

Norsharina I, Maznah I, Aied A, Ghany A. Thymoquinone rich fraction from Nigella sativa and thymoquinone are cytotoxic towards colon and leukaemic carcinoma cell lines. J Med Plants Res. 2011;5(15):3359-66.

Swamy SM, Huat BT. Intracellular glutathione depletion and reactive oxygen species generation are important in e-hederin-induced apoptosis of P388 cells. Mol Cell Biochem. 2003;245(1-2):127-39.

Chehl N, Chipitsyna G, Gong Q, Yeo C J, Arafat HA. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB. 2009;11(5):373-81.

El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker J, Hartig R, Roessner A, et al. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Clin Transl Oncol. 2015;17(2):145-51.

Norsharina I, Maznah I, Aied A, Ghany A. Thymoquinone rich fraction from Nigella sativa and thymoquinone are cytotoxic towards colon and leukaemic carcinoma cell lines. J Med Plants Res. 2011;5(15):3359-66.

Swamy SM, Huat BT. Intracellular glutathione depletion and reactive oxygen species generation are important in e-hederin-induced apoptosis of P388 cells. Mol Cell Biochem. 2003;245(1-2):127-39.
thymohydroquinone in vitro and in vivo. Exp Oncol. 2006;28(3):220-4.

121. Effenberger-Neidnicht K, Schobert R. Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother Pharmacol. 2011;67(4):867-74.

122. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 2008;7(7):1789-96.

123. Li F, Rajendran P, Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol. 2010;161(3):541-54.

124. Al-Sheddi ES, Farshori NN, Al-Oqail MM, Musarrat J, Al-Khedhairy AA, Siddiqui MA. Cytotoxicity of Nigella sativa seed oil and extract against human lung cancer cell line. Asian Pac J Cancer Prev. 2014;15(2):983-7.

125. Peng L, Liu A, Shen Y, Xu HZ, Yang SZ, Ying XZ, et al. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway. Oncol Rep. 2013;29(2):571-8.

126. Hussain AR, Ahmed M, Ahmed S, Manogaran P, Plantanias LC, Alvi SN, et al. Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. Free Radic Biol Med. 2011;50(8):978-87.

127. Bai T, Lian LH, Wu YL, Wan Y, Nan JX. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol. 2013;15(2):275-81.

128. Paramasivam A, Sambantham S, Shabnam J, Raghu-nandhakumar S, Anandan B, Rajiv R, et al. Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP. Toxicol Lett. 2012;213(2):151-9.

129. el-Aziz MA, Hassan HA, Mohamed MH, Meki AR, Abdel-Ghaffar SK, Hussein MR. The biochemical and morphological alterations following administration of melatonin, retinoic acid and Nigella sativa in mammary carcinoma: an animal model. Int J Exp Pathol. 2005;86(6):383-96.

130. Salim EI. Cancer chemopreventive potential of volatile oil from black cumin (Nigella sativa L.) seeds against rat colon carcinogenesis. Nutr Cancer. 2003;45(2):195-202.

131. Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X, et al. Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophy Res Commun. 2012;417(2):864-8.

132. Fathy M, Nikaido T. In vivo modulation of iNOS pathway in hepatocellular carcinoma by Nigella sativa. Environ Health Prev Med. 2013;18(5):377-85.

133. Attoub S, Sperandio O, Raza H, Arafat K, Al-Salam S, Al Sultan M A, et al. Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam Clin Pharmacol. 2013;27(5):557-69.

134. Salim EI. Cancer chemopreventive potential of volatile oil from black cumin seeds, Nigella sativa L., in a rat multi-organ carcinogenesis bioassay. Oncol Lett. 2010;1(5):913-24.

135. Kundu JK, Liu L, Shin JW, Surh YJ. Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cyto-protective enzymes in mouse skin in vivo. Biochem Biophys Res Commun. 2013;438(4):721-7.